Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Trojano

Showing results (141-150 of 342) with videos related to

Pageof 35
Sort By:
Cellular Signalling|May 22, 2002
Interferon beta-1a counteracts effects of activation on the expression of G-protein-coupled receptor kinases 2 and 3, beta-arrestin-1, and regulators of G-protein signalling 2 and 16 in human mononuclear leukocytesMaurizio Giorelli, Paolo Livrea, Giovanni Defazio, et al.
European Journal of Neurology|June 9, 2023
Relapse-associated worsening in a real-life multiple sclerosis cohort: the role of age and pyramidal phenotypeAurora Zanghì, Simonetta Galgani, Paolo Bellantonio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 6, 2021
A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosisMaria Trojano, Lluís Ramió-Torrentà, Luigi Me Grimaldi, et al.
BMC Psychology|July 14, 2023
Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patientsMadia M Biasi, Alessia Manni, Ilaria Pepe, et al.
Journal of Neurology|January 13, 2005
European validation of a standardized clinical description of multiple sclerosisMaria Pia Amato, Jerome Grimaud, Iuliana Achiti, et al.
Journal of Neurology|October 9, 2021
Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosisMassimo Filippi, Romano Danesi, Tobias Derfuss, et al.
Therapeutic Advances in Neurological Disorders|December 25, 2010
Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS StudyFrancesco Patti, Maria Pia Amato, Stefano Bastianello, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 3, 2023
Perspectives on Neuromyelitis Optica Spectrum Disorders, the Narrative Medicine contribution to careMassimo Filippi, Giovanna Borriello, Francesco Patti, et al.
Neurology|February 12, 2016
Recommendations for observational studies of comorbidity in multiple sclerosisRuth Ann Marrie, Aaron Miller, Maria Pia Sormani, et al.
Annals of Neurology|April 21, 2007
New natural history of interferon-beta-treated relapsing multiple sclerosisMaria Trojano, Fabio Pellegrini, Aurora Fuiani, et al.
Pageof 35

Showing results (141-150 of 342) with videos related to

Sort By:
Pageof 35
Cellular Signalling|May 22, 2002
Interferon beta-1a counteracts effects of activation on the expression of G-protein-coupled receptor kinases 2 and 3, beta-arrestin-1, and regulators of G-protein signalling 2 and 16 in human mononuclear leukocytesMaurizio Giorelli, Paolo Livrea, Giovanni Defazio, et al.
European Journal of Neurology|June 9, 2023
Relapse-associated worsening in a real-life multiple sclerosis cohort: the role of age and pyramidal phenotypeAurora Zanghì, Simonetta Galgani, Paolo Bellantonio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 6, 2021
A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosisMaria Trojano, Lluís Ramió-Torrentà, Luigi Me Grimaldi, et al.
BMC Psychology|July 14, 2023
Impact of depression on the perception of fatigue and information processing speed in a cohort of multiple sclerosis patientsMadia M Biasi, Alessia Manni, Ilaria Pepe, et al.
Journal of Neurology|January 13, 2005
European validation of a standardized clinical description of multiple sclerosisMaria Pia Amato, Jerome Grimaud, Iuliana Achiti, et al.
Journal of Neurology|October 9, 2021
Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosisMassimo Filippi, Romano Danesi, Tobias Derfuss, et al.
Therapeutic Advances in Neurological Disorders|December 25, 2010
Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS StudyFrancesco Patti, Maria Pia Amato, Stefano Bastianello, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 3, 2023
Perspectives on Neuromyelitis Optica Spectrum Disorders, the Narrative Medicine contribution to careMassimo Filippi, Giovanna Borriello, Francesco Patti, et al.
Neurology|February 12, 2016
Recommendations for observational studies of comorbidity in multiple sclerosisRuth Ann Marrie, Aaron Miller, Maria Pia Sormani, et al.
Annals of Neurology|April 21, 2007
New natural history of interferon-beta-treated relapsing multiple sclerosisMaria Trojano, Fabio Pellegrini, Aurora Fuiani, et al.
Pageof 35